OKYO
OKYO PharmaOKYO
OKYO
About: OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Employees: 3
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
17% more funds holding
Funds holding: 6 [Q3] → 7 (+1) [Q4]
16% more capital invested
Capital invested by funds: $1.02M [Q3] → $1.18M (+$159K) [Q4]
0.07% more ownership
Funds ownership: 2.95% [Q3] → 3.03% (+0.07%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
343%
upside
Avg. target
$7
343%
upside
High target
$7
343%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 33% 1-year accuracy 57 / 173 met price target | 343%upside $7 | Buy Reiterated | 18 Feb 2025 |
Financial journalist opinion
Based on 3 articles about OKYO published over the past 30 days
Positive
Proactive Investors
22 hours ago
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phase 2 trial being conducted at the Tufts Medical Center in Boston, Massachusetts, early, with 17 patients having completed the study.
Neutral
GlobeNewsWire
1 day ago
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces plans to accelerate the clinical development of urcosimod to treat NCP through the analysis of its data following the early closure of its Phase 2 trial.
Positive
Proactive Investors
3 weeks ago
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company's recent developments, including the formal naming of its drug candidate OK-101 as urcosimod. Jacob discussed the company's recent Fast Track application to the FDA, aimed at accelerating the regulatory pathway for urcosimod.
Positive
Proactive Investors
1 month ago
OKYO Pharma reports long-term shelf stability of corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules. The biopharmaceutical company's confirmation that urcosimod remains stable for over two and a half years in single-use ampoules – small, sealed containers designed to hold a single dose of liquid medication – is an important step in bringing the company closer to submitting a successful New Drug Application (NDA) for FDA approval.
Neutral
GlobeNewsWire
1 month ago
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that the Company has successfully established that urcosimod (formerly known as OK-101) has been shown to be stable for over two and a half years in single-use ampoules used for administration of the drug to patients. Urcosimod is presently in a Phase 2b, randomized, placebo-controlled, double-masked, 48-patient clinical trial to treat NCP patients.
Positive
Proactive Investors
1 month ago
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pain (NCP). The FDA's Fast Track designation is intended to accelerate the development and review of treatments for serious conditions with unmet medical needs, potentially expediting urcosimod's path to market if it is granted.
Positive
Proactive Investors
2 months ago
OKYO Pharma secures USAN designation ‘urcosimod' for lead asset
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod." The company said the designation reinforces its progress in developing treatments for unmet medical needs in ophthalmology, such as neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED).
Positive
Proactive Investors
2 months ago
OKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believe
OKYO Pharma Ltd (NASDAQ:OKYO) is uniquely positioned to emerge as a key player in the ocular treatment arena as it advances its lead therapeutic candidate OK-101, analysts at Goldman Small Cap Research believe. The company is focused on developing OK-101 to treat neuropathic corneal pain (NCP), which has no Food and Drug Administration (FDA)-approved treatment.
Positive
Proactive Investors
2 months ago
OKYO Pharma insiders acquire shares
OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief executive officer Gary Jacob has purchased 10,000 of the company's shares at US$1.04 per share. Additionally, Panetta Partners, in which executive chairman Gabriele Cerrone holds a beneficial interest, purchased 20,000 shares at the same price.
Neutral
GlobeNewsWire
2 months ago
OKYO Pharma Announces Chairman and CEO Acquire Shares
LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, announced today that it has been notified that the Chief Executive Officer, Gary S. Jacob, has purchased 10,000 of the Company's ordinary shares on NASDAQ at a price of US$1.04 per share.
Charts implemented using Lightweight Charts™